查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423334

医院获得性疾病检测市场报告（依适应症分类）（UTI（泌尿道感染）、SSI（手术部位感染）、肺炎、血流感染、MRSA（抗甲氧西林金黄色葡萄球菌）等）及地区2024 -2032

Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球医院获得性疾病检测市场规模达到121亿美元。展望未来， IMARC Group预计到2032年该市场将达到466亿美元，2024-2032年复合年增长率（CAGR）为15.6%。

医院获得性感染 (HAI) 或医院感染是在医院和医疗诊所获得的疾病。院内感染是指源自医院的感染或疾病。即使在疗养院、復健中心、医院或任何其他临床环境附近，一个人也可能患上此类疾病。大多数人在加护病房 (ICU) 和急诊室 (ER) 时都会罹患 HAI。一般来说，这些疾病的潜伏期为入院后48小时至4天不等。医院获得性疾病的一个主要原因是医院内部工作人员缺乏适当的卫生习惯。其他原因可能包括维护程度低于标准、医院工作人员的自满情绪以及多重抗药性微生物 (MDRO) 的增加。一些最常见的院内感染包括肺炎、原发性血流感染、泌尿道感染等。在许多情况下，也发现这些院内感染有时可追溯到患者自身的微生物组。当保护性皮肤层接触到可能的威胁并导致感染时，尤其是在外科手术后，就会发生这种情况。

市场走向：

在人口成长和医疗基础设施现代化的推动下，全球医疗保健设施的数量大幅增加。这导致医院感染发病率上升，推动了医院获得性疾病检测的需求。此外，随着先进技术和科学创新，市场上现在有各种用于预防、诊断和监测 HAI 的技术，如微阵列、聚合酶链反应 (PCR)、即时定位系统 (RTLS) 和固相杂交。 RTLS 等技术可以轻鬆防止 HAI 在患者和工作人员中传播。患者对医院感染的认识不断提高，以及政府颁布法规对医院感染发生率高的医院进行处罚，这些都是促进市场成长的其他因素。

本报告回答的关键问题

  • 2023年全球医院获得性疾病检测市场规模有多大？
  • 2024-2032 年全球医院获得性疾病检测市场成长率为何？
  • 全球医院获得性疾病检测市场的驱动因素是什么？
  • 全球医院获得性疾病检测市场的主要行业趋势是什么？
  • COVID-19对全球医院获得性疾病检测市场有何影响？
  • 全球医院获得性疾病检测市场依适应症划分是怎样的？
  • 全球医院获得性疾病检测市场主要有哪些地区？
  • 全球医院获得性疾病检测市场的主要公司/参与者有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球医院获得性疾病检测市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场区隔：依指标
  • 市场区隔：按地区
  • 市场预测
  • SWOT分析
    • 概述
    • 优势
    • 弱点
    • 机会
    • 威胁
  • 价值链分析
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价格分析

第 6 章：市场区隔：依迹象

  • UTI（泌尿道感染）
    • 市场走向
    • 市场预测
  • SSI（手术部位感染）
    • 市场走向
    • 市场预测
  • 肺炎
    • 市场走向
    • 市场预测
  • 血流感染
    • 市场走向
    • 市场预测
  • MRSA（抗甲氧西林金黄色葡萄球菌）
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按地区

  • 北美洲
    • 市场走向
    • 市场预测
  • 欧洲
    • 市场走向
    • 市场预测
  • 亚太地区
    • 市场走向
    • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场预测
  • 拉丁美洲
    • 市场走向
    • 市场预测

第 8 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Alere, Inc.
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • QIAGEN
    • Siemens Healthcare
    • Diatherix Laboratories, Inc.
    • Meridian Bioscience, Inc.
    • Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
    • Cepheid, Inc.
Product Code: SR112024A1128

Abstract

The global hospital acquired disease testing market size reached US$ 12.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 46.6 Billion by 2032, exhibiting a growth rate (CAGR) of 15.6% during 2024-2032.

Hospital-acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital-acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Other reasons can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patient's own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

Market Trends:

Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital acquired disease testing market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on indication.

Breakup by Indication:

UTI (Urinary Tract Infection)

SSI (Surgical Site Infection)

Pneumonia

Bloodstream Infections

MRSA (Methicillin-Resistant Staphylococcus Aureus)

Others

Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.

Regional Insights:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Competitive Landscape:

The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMerieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.

This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.

Key Questions Answered in This Report

  • 1. What is the market size for the global hospital acquired disease testing market 2023?
  • 2. What is the global hospital acquired disease testing market growth 2024-2032?
  • 3. What are the global hospital acquired disease testing market drivers?
  • 4. What are the key industry trends in the global hospital acquired disease testing market?
  • 5. What is the impact of COVID-19 on the global hospital acquired disease testing market?
  • 6. What is the global hospital acquired disease testing market breakup by indication?
  • 7. What are the major regions in the global hospital acquired disease testing market?
  • 8. Who are the key companies/players in the global hospital acquired disease testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Acquired Disease Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Indication
  • 5.5 Market Breakup by Region
  • 5.6 Market Forecast
  • 5.7 SWOT Analysis
    • 5.7.1 Overview
    • 5.7.2 Strengths
    • 5.7.3 Weaknesses
    • 5.7.4 Opportunities
    • 5.7.5 Threats
  • 5.8 Value Chain Analysis
  • 5.9 Porters Five Forces Analysis
    • 5.9.1 Overview
    • 5.9.2 Bargaining Power of Buyers
    • 5.9.3 Bargaining Power of Suppliers
    • 5.9.4 Degree of Competition
    • 5.9.5 Threat of New Entrants
    • 5.9.6 Threat of Substitutes
  • 5.10 Price Analysis

6 Market Breakup by Indication

  • 6.1 UTI (Urinary Tract Infection)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 SSI (Surgical Site Infection)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Pneumonia
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Bloodstream Infections
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Europe
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Asia Pacific
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Middle East and Africa
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Latin America
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Key Players
  • 8.3 Profiles of Key Players
    • 8.3.1 Abbott Laboratories
    • 8.3.2 Alere, Inc.
    • 8.3.3 Becton, Dickinson and Company
    • 8.3.4 bioMerieux SA
    • 8.3.5 F. Hoffmann-La Roche Ltd.
    • 8.3.6 Hologic, Inc.
    • 8.3.7 QIAGEN
    • 8.3.8 Siemens Healthcare
    • 8.3.9 Diatherix Laboratories, Inc.
    • 8.3.10 Meridian Bioscience, Inc.
    • 8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
    • 8.3.12 Cepheid, Inc.

List of Figures

  • Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2023
  • Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2023
  • Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
  • Figure 7: Global: Hospital Acquired Disease Testing Industry: Value Chain Analysis
  • Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter's Five Forces Analysis
  • Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
  • Table 5: Global: Hospital Acquired Disease Testing Market: Key Players